The proposed mechanistic pathways ensure the significance of TNFR1 and MADD interactions that could be used as a novel target for development of drugs for the treatment of Alzheimer’s disease. The gene discussed is MADD; the disease is early-onset autosomal dominant Alzheimer disease.